Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1347510
PUBLISHER: IMARC | PRODUCT CODE: 1347510
Doxorubicin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
PUBLISHED:
PAGES: 149 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Market Overview:
The global doxorubicin market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.04% during 2023-2028.
Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, Wilms' tumor, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.
Doxorubicin Market Trends:
The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global doxorubicin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on application and distribution channel.
Breakup by Application:
Breast Cancer
Ovarian Cancer
Multiple Myeloma
Kaposi Sarcoma
Leukemia
Bone Sarcoma
Endometrial Cancer
Others
Breakup by Distribution Channel:
Hospital and Retail Pharmacies
Online Stores
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.
Key Questions Answered in This Report:
- How has the global doxorubicin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global doxorubicin market?
- What are the key regional markets?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global doxorubicin market and who are the key players?
- What is the degree of competition in the industry?
Product Code: SR112023A5677
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Doxorubicin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Application
- 6.1 Breast Cancer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Ovarian Cancer
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Multiple Myeloma
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Kaposi Sarcoma
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Leukemia
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Bone Sarcoma
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Endometrial Cancer
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Others
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Hospital and Retail Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Online Stores
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.2 Baxter International Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Cadila Pharmaceuticals
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Cipla Inc.
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Hikma Pharmaceuticals PLC
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.6 Meiji Holdings Co. Ltd.
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Novartis AG
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Pfizer Inc.
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.8.4 SWOT Analysis
- 13.3.1 Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
Product Code: SR112023A5677
List of Figures
- Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
- Figure 2: Global: Doxorubicin Market: Sales Value (in Billion US$), 2017-2022
- Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion US$), 2023-2028
- Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2022
- Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2022
- Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2022
- Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 29: North America: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 31: United States: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 33: Canada: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 37: China: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 39: Japan: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 41: India: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 45: Australia: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 49: Others: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 51: Europe: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 53: Germany: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 55: France: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 59: Italy: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 61: Spain: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 63: Russia: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 65: Others: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 73: Others: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
- Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2022
- Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 78: Global: Doxorubicin Industry: SWOT Analysis
- Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
- Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2022 and 2028
- Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2023-2028
- Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
- Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2023-2028
- Table 5: Global: Doxorubicin Market: Competitive Structure
- Table 6: Global: Doxorubicin Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.